Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype
出版年份 2020 全文链接
标题
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype
作者
关键词
-
出版物
Science Translational Medicine
Volume 12, Issue 555, Pages eaax8313
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2020-08-06
DOI
10.1126/scitranslmed.aax8313
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Toward Minimal Residual Disease-Directed Therapy in Melanoma
- (2018) Florian Rambow et al. CELL
- PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways
- (2018) Yulei Zhao et al. MOLECULAR CANCER RESEARCH
- Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy
- (2018) Anuja Sathe et al. PLoS One
- Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
- (2018) Khyati N. Shah et al. NATURE MEDICINE
- A single-cell survey of the small intestinal epithelium
- (2017) Adam L. Haber et al. NATURE
- Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer
- (2017) Claudio Isella et al. Nature Communications
- Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
- (2017) Chunying Song et al. Cancer Discovery
- Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer
- (2017) Min Zou et al. Cancer Discovery
- Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody
- (2016) E. Pupo et al. CANCER RESEARCH
- A Landscape of Pharmacogenomic Interactions in Cancer
- (2016) Francesco Iorio et al. CELL
- A framework for understanding and targeting residual disease in oncogene-driven solid cancers
- (2016) Trever G Bivona et al. NATURE MEDICINE
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- Reg4+deep crypt secretory cells function as epithelial niche for Lgr5+stem cells in colon
- (2016) Nobuo Sasaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EpiMINE, a computational program for mining epigenomic data
- (2016) SriGanesh Jammula et al. Epigenetics & Chromatin
- Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
- (2016) Michael Ramirez et al. Nature Communications
- Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells
- (2016) Albert Bosch-Vilaró et al. Oncotarget
- Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
- (2015) S. M. Leto et al. CLINICAL CANCER RESEARCH
- Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
- (2015) H. J. Jacobsen et al. CLINICAL CANCER RESEARCH
- Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
- (2015) Gideon M. Blumenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- The genomic landscape of response to EGFR blockade in colorectal cancer
- (2015) Andrea Bertotti et al. NATURE
- Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer
- (2015) Alex Gregorieff et al. NATURE
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
- (2015) Luping Lin et al. NATURE GENETICS
- RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
- (2015) Gorjan Hrustanovic et al. NATURE MEDICINE
- Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
- (2015) Maicol Mancini et al. Science Signaling
- IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
- (2015) Eugenia R. Zanella et al. Science Translational Medicine
- Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
- (2015) Sandra Misale et al. Nature Communications
- Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
- (2015) R. Dienstmann et al. Cancer Discovery
- HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
- (2015) S. M. Kavuri et al. Cancer Discovery
- Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
- (2015) Maicol Mancini et al. Science Signaling
- MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors
- (2014) Paolo Luraghi et al. CANCER RESEARCH
- Molecular Pathways: HER3 Targeted Therapy
- (2014) K. Gala et al. CLINICAL CANCER RESEARCH
- Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
- (2014) Andrea Viale et al. NATURE
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Paneth Cells: Maestros of the Small Intestinal Crypts
- (2013) Hans C. Clevers et al. Annual Review of Physiology
- Regulation of Hippo Signaling by EGFR-MAPK Signaling through Ajuba Family Proteins
- (2013) B.V.V.G. Reddy et al. DEVELOPMENTAL CELL
- Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2013) Hubert Piessevaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Intestinal label-retaining cells are secretory precursors expressing Lgr5
- (2013) Simon J. A. Buczacki et al. NATURE
- A unifying theory for the crypt
- (2013) Hans Clevers NATURE
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor growth dynamics: insights into evolutionary processes
- (2013) Ignacio A. Rodriguez-Brenes et al. TRENDS IN ECOLOGY & EVOLUTION
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- Identifying the Stem Cell of the Intestinal Crypt: Strategies and Pitfalls
- (2012) Nick Barker et al. Cell Stem Cell
- LAS: A Software Platform to Support Oncological Data Management
- (2012) Elena Baralis et al. JOURNAL OF MEDICAL SYSTEMS
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Role of YAP/TAZ in mechanotransduction
- (2011) Sirio Dupont et al. NATURE
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin
- (2010) Tanvi S. Jani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
- (2009) H. Piessevaux et al. ANNALS OF ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started